MBOT - NASDAQ
Microbot Medical Inc.
$1.97
-0.51%Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company, through its ViRob, TipCAT, CardioSert, and Liberty micro-robotic technologies, developing Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; a disposable robot for various endovascular interventional procedures; and a multi generation pipeline portfolio. It has 42 issued/allowed patents and 23 patent applications pending worldwide. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts.
At a Glance
Live Snapshotmbot
Total Payables
Last Annual Value
511.00K
3-Year CAGR
64%
5-Year CAGR
13%
10-Year CAGR
35%
Microbot Medical Inc. Competitors Analysis of Total Payables
| Company | Total Payables | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Microbot Medical Inc. NASDAQ:MBOT | 511.00K | 12.7% | 12.9% | -0.0% | |
 DocGo Inc. NASDAQ:DCGO | 11.45M | -25.5% | -6.3% | N/A | |
 Clene Inc. NASDAQ:CLNN | 892.00K | -16.0% | -14.2% | N/A | |
 Oramed Pharmaceuticals Inc. NASDAQ:ORMP | 14.98M | 200.7% | 41.9% | N/A | |
 Apyx Medical Corporation NASDAQ:APYX | 3.06M | 4.1% | -9.1% | 6.7% | |
 Atossa Therapeutics, Inc. NASDAQ:ATOS | 4.29M | 74.6% | 20.1% | 17.4% | |
 biote Corp. NASDAQ:BTMD | 6.83M | 17.8% | 9.4% | N/A | |
 Citius Oncology, Inc. NASDAQ:CTOR | 13.23M | 117.3% | N/A | N/A | |
 LENSAR, Inc. NASDAQ:LNSR | 18.98M | 67.9% | 47.8% | N/A | |
 Spero Therapeutics, Inc. NASDAQ:SPRO | 1.08M | -15.2% | -0.5% | -0.6% | |
 Sharps Technology, Inc. NASDAQ:STSS | 590.69K | -9.4% | -6.0% | N/A |
Microbot Medical Inc. Fair Value Envelope
Related Guides
Continue your MBOT research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.